Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers.

Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez JM, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert JP, Domènech E; ENEIDA registry by GETECCU.

Am J Gastroenterol. 2019 May;114(5):771-776. doi: 10.14309/ajg.0000000000000210.

PMID:
31082839
2.

Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.

Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S; New York Crohn's and Colitis Organization.

Clin Gastroenterol Hepatol. 2016 Jan;14(1):58-64. doi: 10.1016/j.cgh.2015.07.037. Epub 2015 Aug 3.

PMID:
26247164
3.

Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.

Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardiola J, Mínguez M, Calvet X, Márquez L, Fernández Salazar LI, Bujanda L, García C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M, Alcaín G, García-Sánchez V, Panés J, Domènech E, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP.

Am J Gastroenterol. 2017 Jul;112(7):1135-1143. doi: 10.1038/ajg.2017.96. Epub 2017 May 23.

PMID:
28534520
4.

Previous Cancer/Lymphoma and Refractory Inflammatory Bowel Disease.

Bernheim O, Axelrad J, Itzkowitz SH, Colombel JF.

Dig Dis. 2015;33 Suppl 1:44-49. Epub 2015 Sep 14.

PMID:
26367257
5.

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.

Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D; le GETAID.

Inflamm Bowel Dis. 2016 Jun;22(6):1362-9. doi: 10.1097/MIB.0000000000000741.

PMID:
26919458
6.

Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.

Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN.

Gastroenterology. 2016 Jul;151(1):97-109.e4. doi: 10.1053/j.gastro.2016.03.037. Epub 2016 Apr 1. Review.

7.

Management of inflammatory bowel disease patients with a cancer history.

Beaugerie L.

Curr Drug Targets. 2014;15(11):1042-8. Review.

PMID:
25146698
8.

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M.

Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11.

PMID:
28193515
9.

Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease.

Mosher CA, Brown GR, Weideman RA, Crook TW, Cipher DJ, Spechler SJ, Feagins LA.

Inflamm Bowel Dis. 2018 Feb 15;24(3):617-623. doi: 10.1093/ibd/izx046.

PMID:
29390104
10.

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study.

Biancone L, Armuzzi A, Scribano ML, D'Inca R, Castiglione F, Papi C, Angelucci E, Daperno M, Mocciaro F, Riegler G, Fries W, Meucci G, Alvisi P, Spina L, Ardizzone S, Petruzziello C, Ruffa A, Kohn A, Vecchi M, Guidi L, Di Mitri R, Renna S, Emma C, Rogai F, Rossi A, Orlando A, Pallone F; Italian Group for the study of Inflammatory Bowel Disease.

J Crohns Colitis. 2016 Aug;10(8):913-24. doi: 10.1093/ecco-jcc/jjw048. Epub 2016 Mar 1.

11.

Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.

Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD.

Arthritis Rheumatol. 2016 Oct;68(10):2403-11. doi: 10.1002/art.39738.

12.

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.

Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD.

JAMA Dermatol. 2016 Feb;152(2):164-72. doi: 10.1001/jamadermatol.2015.3029.

13.

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

Cheddani H, Dauchet L, Fumery M, Charpentier C, Marie Bouvier A, Dupas JL, Pariente B, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C.

Am J Gastroenterol. 2016 Oct;111(10):1428-1436. doi: 10.1038/ajg.2016.304. Epub 2016 Aug 2.

PMID:
27481308
14.

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R.

JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071.

15.

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.

Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):735-44. doi: 10.1002/pds.3621. Epub 2014 Apr 30.

PMID:
24788825
18.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
19.

Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines.

Khan N, Lee H, Trivedi C, Kavani H, Medvedeva E, Xie D, Lewis JD, Yang YX.

Clin Gastroenterol Hepatol. 2019 Mar 7. pii: S1542-3565(19)30254-X. doi: 10.1016/j.cgh.2019.03.005. [Epub ahead of print]

PMID:
30853615
20.

Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.

Clowry J, Sheridan J, Healy R, Deady S, Keegan D, Byrne K, Cullen G, Mulcahy H, Comber H, Parnell AC, Doherty G, Lally A.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):978-985. doi: 10.1111/jdv.14105. Epub 2017 Feb 17.

PMID:
28045204

Supplemental Content

Support Center